Clozapine과 Olanzapine을 복용한 정신분열병 환자의 고혈압 발생률 = The Incidence Rate of Hypertension in Schizophrenic Patients Treated with Clozapine or Olanzapine

참고문헌 (Reference)

1 강자영, "본태성 고혈압 환자에서 안지오텐신 수용체 차단제irbesartan에 의한 혈관 경직도의 개선" 대한내과학회 67 (67): 241-248, 2004

2 Sachs GS, "Weight gain associated with use of psy-chotropic medications" 60 (60): 16-19, 1999

3 Povlsen UJ, "Tolerability and the-rapeutic effect of clozapine:a retrospective investigation of 216 patients treated with clozapine for up to 12 years" 71 : 176-185, 1985

4 Melzer HY, "The fourth generation of progress Edited by Blom FE" Raven Press 1277-1286, 1995

5 Naber D, "The European experience with clozapine" 41 : 886-890, 1990

6 Littrel K, "Switching clozapine responders to olanzapine" 61 : 912-915, 2000

7 NICE guidelines, "Schizophrenia, core interventions in the treat-ment and management of schizophrenia in primary and secon-dary care" London: National Collaborating Centre for Mental Health 2002

8 "Safety of olanzapine" 58 (58): 13-17, 1997

9 Davidson M, "Risk of cardiovascular disease and sudden death in schizophrenia" 63 (63): 5-1, 2002

10 Meltzer HY, "Putting metabolic side effects into perspective:risks versus benefits of atypical antipsychotics" 62 (62): 35-39, 2001

11 "Physical consequences of schizoph-renia and its treatment: the metabolic syndrome" 71 : 239-257, 2002

12 Gupta S, "Paradoxical hypertension associ-ated with clozapine [leter]" 151 : 148-, 1994

13 "Longitudinal comparative study of ris-peridone and conventional neuroleptics for treating patients with schizophrenia" The Quebec Schizophrenia Study Group 20 : 295-304, 2000

14 "Hypertension after initiation of cloza-pine[letter]" 153 : 1368-1369, 1996

15 "Estimating the consequences of anti-psychotic induced weight gain on health and mortality rate" 101 : 277-28, 2001

16 "Epidemiological approa-ches to heart disease:the Framingham Study" 41 : 279-286, 1951

17 Liebermann JA, "Clozapine:guidelines for clinical management" 62 : 22-31, 201

18 Ereshefsky L, "Clozapine:an atypical antipsychotic agent" 8 : 691-709, 1989

19 Baldessarini RJ, "Clozapine:a novel antipsy-chotic agent" 324 : 746-754, 191

20 Lund BC, "Clozapine use in patients with schizophrenia and the risk of diabetes,hyperlipi-demia,and hypertension:a claims-based approach" 58 : 1172-1176, 2001

21 Kane J, "Clozapine for the treatment-resistant schizophrenia:a double-blind comparison with chlorpromazine" 45 : 789-796, 1988

22 "Clozapine and hypertension:A chart review of 82 patients" 65 : 686-689, 2004

23 Frankenburg FR, "Cloza-pine and body mass change" 43 : 520-524, 1998

24 Richelson E, "Binding of antipsychotic drugs to human brain receptors focus on newer generation compounds." 68 : 29-39, 2000

25 Acker J, "Autonomic responses of blood vessels and sweat glands in patients with schizophrenia treated with olanzapine or clozapine" 154 : 368-72, 2001

26 Cohen H, "Association of autonomic dysfunction and clozapine" 179 : 167-71, 2001

27 "Antipsychotic-induced hyperlipidemia among people with schizophrenia. Presented at the 156th annual meeting of the American Psychiatric As-sociation" San Fransisco, Calif 17 (17): 2003

28 Conley RR, "Adverse events related to olanzapine" 61 (61): 26-29, 2000

29 "Actual causes of death in the United States, 2000" 291 : 1238-1245, 2004